Mirtazapina Psidep 15 Mg Comprimidos Revestidos (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapina Psidep 15 Mg Comprimidos Revestidos, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as a 15 mg coated tablet for oral use. It treats major depressive disorder in adult patients.

GNH USA supplies Mirtazapina Psidep 15 Mg Comprimidos Revestidos as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Mirtazapine is indicated for depressive disorders, acting on noradrenergic and serotonergic pathways.

- Major depressive disorder: reduces depressive symptoms and improves overall mood in adults. - Depressive episodes with anxiety features: alleviates both mood and anxiety symptoms, supporting functional recovery.

Mirtazapine may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Peripheral edema

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Aseptic meningitis - Hepatotoxicity - Emergence of suicidal thoughts, especially early in treatment - Severe hypotension or cardiac arrhythmia

Before initiating therapy, clinicians should consider several safety aspects.

- Assess psychiatric history: evaluate for suicidal ideation prior to treatment. - Monitor weight: patients may experience significant weight gain. - Check liver function: use caution in hepatic impairment. - Avoid abrupt discontinuation: taper dose to reduce withdrawal symptoms. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original packaging.

Mirtazapine can interact with other medicines; awareness of major and moderate interactions helps ensure safe use.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis or serotonin syndrome. - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine plasma concentrations. - CNS depressants (e.g., benzodiazepines, alcohol): additive sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - Other serotonergic agents (e.g., SSRIs, SNRIs): potential for serotonin syndrome. - Potent CYP3A4 inducers (e.g., rifampicin, carbamazepine): may lower mirtazapine exposure.